DrugsNews.net

Drugs Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Pembrolizumab"

The FDA ( Food and Drug Administration ) has granted accelerated approval to Keytruda ( Pembrolizumab ) for treatment of patients with advanced or unresectable melanoma who are no longer responding to ...


The FDA ( Food and Drug Administration ) has granted Breakthrough Therapy Designation to Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, for the treatment of patients with Epidermal Growth Factor Re ...


The FDA ( Food and Drug Administration ) has granted accelerated approval to Opdivo ( Nivolumab ), a new treatment for patients with unresectable ( cannot be removed by surgery ) or metastatic ( advan ...


The FDA ( Food and Drug Administration ) has granted accelerated approval for Keytruda ( Pembrolizumab ) to treat patients with advanced ( metastatic ) non-small cell lung cancer ( NSCLC ) whose disea ...


The FDA ( Food and Drug Administration ) has approved Opdivo ( Nivolumab ) to treat patients with advanced ( metastatic ) non-small cell lung cancer whose disease progressed during or after Platinum-b ...


The FDA ( Food and Drug Administration ) has approved a new second-generation lung cancer treatment that can help many patients in their battle against the disease. Lung cancer patients got another ro ...


The Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death receptor-1 ) therapy, at a fixed dose of 200 mg every three weeks, for the treatment ...


The European Commission ( EC ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 therapy, at a dose of 2 mg/kg every three weeks, for patients with locally advanced or metastatic non-small cell l ...


The Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab), an anti-PD-1 ( programmed death receptor-1 ) therapy, for the first-line treatment of patients with metastatic non-smal ...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Keytruda ( Pembrolizumab ) for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphom ...


The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death receptor-1 ) therapy, for the treatment of adult and pediatric patients with ref ...


In non-small cell lung cancer ( NSCLC ) that has already formed metastases, the suitable treatment depends, among other factors, on the genes that are activated in the tumour cells and whether mutatio ...


Early data from two clinical trials have shown reduced survival with Keytruda ( Pembrolizumab ) and Tecentriq ( Atezolizumab ) when used as first-line treatments for urothelial cancer ( cancer of the ...


The European Commission has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with Pemetrexed ( Alimta ) and Platinum chemotherapy for the first-line treatment of metastatic no ...


The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with Carboplatin and either Paclitaxel or nab-Paclitaxel, for the first-line ...